



(12) **United States Patent
Horn**

(10) **Patent No.:** US 8,293,742 B2
(45) **Date of Patent:** Oct. 23, 2012

(54) **PREFERENTIAL VASOCONSTRICTION
COMPOSITIONS AND METHODS OF USE**

(75) Inventor: **Gerald Horn**, Deerfield, IL (US)

(73) Assignee: **Alpha Synergy Development, Inc.**,
Dana Point, CA (US)

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 385 days.

(21) Appl. No.: **12/460,941**

(22) Filed: **Jul. 27, 2009**

(65) **Prior Publication Data**

US 2010/0029659 A1 Feb. 4, 2010

Related U.S. Application Data

(60) Provisional application No. 61/137,714, filed on Aug.
1, 2008, provisional application No. 61/192,777, filed
on Sep. 22, 2008, provisional application No.
61/203,120, filed on Dec. 18, 2008, provisional
application No. 61/207,481, filed on Feb. 12, 2009.

(51) **Int. Cl.**

A61K 31/498 (2006.01)

A61P 27/02 (2006.01)

(52) **U.S. Cl.** **514/249**

(58) **Field of Classification Search** 514/249
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,663,340	A	5/1987	Najer et al.	
5,021,416	A	6/1991	Gluchowski	
5,300,504	A	4/1994	Gluchowski	
5,424,078	A	6/1995	Dziabo et al.	
5,561,132	A	10/1996	Burke et al.	
5,677,321	A	10/1997	Jeon et al.	
5,756,503	A	5/1998	Burke et al.	
5,804,587	A	9/1998	Cupps et al.	
5,914,342	A	6/1999	Maurer et al.	
5,916,900	A	6/1999	Cupps et al.	
5,948,804	A	9/1999	Jeon et al.	
5,965,595	A	10/1999	Maurer et al.	
6,040,451	A	3/2000	Jeon et al.	
6,087,361	A	7/2000	Munk et al.	
6,110,952	A	8/2000	Henry et al.	
6,117,871	A	9/2000	Maurer et al.	
6,159,998	A	12/2000	Jeon et al.	
6,162,818	A	12/2000	Henry et al.	
6,242,442	B1	6/2001	Dean et al.	
6,534,048	B1	3/2003	Borgman	
6,562,873	B2	5/2003	Olejnik et al.	
6,627,210	B2	9/2003	Olejnik et al.	
6,641,834	B2	11/2003	Olejnik et al.	
6,673,337	B2	1/2004	Olejnik et al.	
6,730,065	B1	5/2004	Horn	
6,982,079	B2	1/2006	Huth	
7,019,149	B2*	3/2006	Burk et al.	549/228
2005/0020600	A1	1/2005	Scherer	

OTHER PUBLICATIONS

Lee, "Efficacy of brimonidine tartrate 0.2% ophthalmic solution in
reducing halos after laser in situ keratomileusis", J Cataract Refract
Surg 2008, (34), pp. 963-967.*
Mechanism of decongestant activity of α_2 -adrenoceptor agonists,

Alpha-adrenoceptor agonistic activity of oxymetazoline and
xylometazoline, Haenisch B. et al., Fundam Clin Pharmacol. Dec. 17,
2009.

An Evaluation of Nasal Response Following Different Treatment
Regimes of . . . , Morris S. et al., American Journal Rhinology, vol. 11,
No. 2, Mar.-Apr. 1997, pp. 109-115(7).

Pharmacological Characterization of Postjunctional α -Adrenocep-
tors in . . . , Corboz M.R. et al., American Jour of Rhinology, vol. 19,
No. 5, Sep.-Oct. 2005, pp. 495-502(8).

Postjunctional α_2 -adrenoceptors in blood vessels of human nasal
mucosa, Ichimura K. et al., Arch Otorhinolaryngol (1988) 245:127-
131.

Long-term use of oxy- and xylometazoline nasal sprays induces
rebound swelling, tolerance, and nasal hyperreactivity, Graf P.,
Rhinology 1996, 34(1):9-13.

Alpha 1-receptors at pre-capillary resistance vessels of the human
nasal mucosa, Johannssen V et al., Rhinology 1997; 35(4):161-65.

Correspondence A Propos De L'article: <<Traitement Des
Glaucomes Par La Brimonidine>>, M. Detry-Morel Et C. Dutrieux<
J Fr Ophtalmo1.2001; 24(7): 748-9.

Potent α_2A -Adrenoceptor-Mediated Vasoconstriction by
Brimonidine in Porcine Ciliary Arteries, Anna Wikberg-Matsson, et
al., IOVS, 2001, vol. 42, No. 9, 2049-55.

Medical Management of Chronic Rhinosinusitis—Jean P. Fong,
MD, Matthew Ryan, MD (May 2006).

Preven Drugs from Going Missing in Action—Mark B. Abelson,
MD, and Sarah A. Rosner MPH; Review of Ophthalmology; www.
revophth.com/index.asp?page=1_357.htm.

Interactions Between CA_{2+} and $H+$ and Functional Consequences in
Vascular Smooth Muscle—C. Austin and S. Wray, Journ. of Amer.
Heart Association (Circ Res. 2000;86:355-363).

A Useful New Topical Treatment for Glaucoma and Ocular Hyper-
tension—Drug Ther Perspect 13(1):1-4, 1999.

Brimonidine in the Treatment of Glaucoma and Ocular Hyperten-
sion—Louis B. Cantor, Therapeutics and Clinical Risk Management
2006;2(4) 337-346.

Silent Bedpartners—Nancy A. Collop, Chest 2002; 122; 1111-1112.

Traitement Des Glaucomes Par La Brimonidine (Alphagan® 0,2
%)—M. Detry-Morel, C. Dutrieux, J FR. Ophtalmol., 2000; 23, 8,
763-768.

Vasopressin-Induced Vasoconstriction: Two Concentration-Depen-
dent Signaling Pathways—Kyle K. Henderson and Kenneth L.
Bryon, J Appl Physiol 102: 1402-1409, 2007.

The Effect of Correction of Sleep-Disordered Breathing on Bp in
Untreated Hypertension—K. Mae Hla, J. B. Skatrud, L. Finn, M.
Palta and T. Young, Chest 2002;122; 1125-1135.

(Continued)

Primary Examiner — Sreeni Padmanabhan

Assistant Examiner — Sahar Javanmard

(74) *Attorney, Agent, or Firm* — Wood, Phillips, Katz, Clark
& Mortimer

(57) **ABSTRACT**

The invention generally relates to compositions and methods
for preferential vasoconstriction of smaller blood vessels
relative to larger blood vessels. The compositions comprise
highly selective α_2 adrenergic receptor agonists, at low
concentrations, such as below 0.05% weight by volume. The
compositions preferably comprise brimonidine. The compo-
sitions preferably have pH between about 5.5 and about 6.5.

6 Claims, 7 Drawing Sheets

OTHER PUBLICATIONS

Myogenic Tone and Reactivity of the Rat Ophthalmic Artery—Y. P. R. Jarajapu, M. B. Grant, and H. J. Knot, *Invest. Ophthalm. & Visual Science*, Jan. 2004, vol. 45, No. 1.

Correspondence A Propos De L'article: <<Traitement Des Glaucomes Par La Brimonidine>>, M. Detry-Morel Et C. Dutrieux, *J Fr Ophtalmol*. 2000; 23(8): 763-8.

Prospective Study of the Association Between Sleep-Disordered Breathing and Hypertension—P. Peppard, et. al., *The New England J of Med.*, vol. 342, No. 19:1378-1384 (2000).

Catecholamines and Sympathomimetic Drugs—Goodman & Gilman's Pharmacology, Ch. 10; www.accessmedicine.com/popup.aspx?aid-936314&pring=yes_chapter.

Rhinitis Medicamentosa—JT Ramey, E Bailen, RF Lockey, *J Investig Allergol Clin Immunol* 2006; vol. 16(3); 148-155.

Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo—D.D. Rees, et al., *br. J. Pharmacol.* (1990) 101, 746-752.

Inhibition of α -adrenergic vasoconstriction in exercising human thigh muscles—D. Walter Wray, et al., *J Physiol* 555, 2 pp. 545-264 (2003).

Dexmedetomidine Enhances the Local Anesthetic Action of Lidocaine via . . . Tatsushi Yoshitomi DDS et al., *Anesth Analg* 2008; 107:96-101.

Adding Dexmedetomidine to Lidocaine for Intravenous Regional Anesthesia, Dilek Memis, MD et al., *Anesth Analg* 2004;98:835-40.

* cited by examiner

FIG. 1




FIG. 2





FIG. 3



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.